OncoMatch/Clinical Trials/NCT03007030
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
Is NCT03007030 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Brentuximab Vedotin for cd30-positive neoplastic cells present.
Treatment: Brentuximab Vedotin — This phase II trial studies how well brentuximab vedotin works in treating patients with CD30 positive (+) malignant mesothelioma that cannot be removed by surgery. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of tumor cells to grow and spread.
Check if I qualifyExtracted eligibility criteria
Cancer type
Mesothelioma
Biomarker criteria
Required: CD30 overexpression (positive immunohistochemical expression)
Positive CD30+ immunohistochemical expression
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: allogeneic bone marrow or organ transplantation
Prior allogeneic bone marrow or organ transplantation
Cannot have received: investigational drug
Patient has received other investigational drugs with 14 days before enrollment
Lab requirements
Blood counts
ANC > 1500/mm^3; Platelets > 100,000/mm^3; Hemoglobin > 8.5 g/dL
Kidney function
Calculated creatinine clearance must be ≥ 30 mL/minute
Liver function
Total bilirubin ≤ 1.5 x ULN; AST and ALT < 3 x ULN (≤ 5 x ULN if with known liver metastases)
ANC > 1500/mm^3; Platelets > 100,000/mm^3; Hemoglobin (Hgb) > 8.5 g/dL; Total bilirubin ≤ 1.5 x ULN; AST and ALT < 3 x ULN (≤ 5 x ULN if with known liver metastases); Calculated creatinine clearance must be ≥ 30 mL/minute
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify